Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biogen's share price for the quarter that ended in Mar. 2024 was $215.63. Biogen's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 145 Mil. Therefore, Biogen's market cap for the quarter that ended in Mar. 2024 was $31,223 Mil.
Biogen's quarterly market cap
increased
from Sep. 2023 ($37,241 Mil) to Dec. 2023 ($37,496 Mil) but then
declined
from Dec. 2023 ($37,496 Mil) to Mar. 2024 ($31,223 Mil).
Biogen's annual market cap
increased
from Dec. 2021 ($35,268 Mil) to Dec. 2022 ($39,876 Mil) but then
declined
from Dec. 2022 ($39,876 Mil) to Dec. 2023 ($37,496 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biogen's Enterprise Value for Today is $35,350 Mil.
Biogen Market Cap Historical Data
The historical data trend for Biogen's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's Market Cap distribution charts can be found below:
* The bar in red indicates where Biogen's Market Cap falls into.
Biogen Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biogen's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (NAS:BIIB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biogen Market Cap Related Terms
Thank you for viewing the detailed overview of Biogen's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIIB has been successfully added to your 